Results 241 to 250 of about 5,785,217 (307)

The Impact of Common Medications on Male Fertility: An Updated Systematic Review

open access: yesAndrology, EarlyView.
ABSTRACT Background Compared with those of cytotoxic treatments, the potential effects of common medications on the fertility of men trying to conceive currently or planning to conceive in the future are less well described. The use of common medications may modify the gonadotropic axis, spermatogenesis, and epididymal maturation or alter male ...
Lina Jebli   +7 more
wiley   +1 more source

Case Report: Allogeneic hematopoietic stem cell transplantation in a patient with acute myeloid leukemia and hepatitis E. [PDF]

open access: yesFront Oncol
Lepek J   +7 more
europepmc   +1 more source

Long‐Term Outcomes After Elective Splenectomy for Haematological Disease: A 27‐Year Single‐Centre Study

open access: yesANZ Journal of Surgery, EarlyView.
Splenectomy is a safe and effective treatment option in selected patients with haematological disease, despite declining referrals over the last 27 years in the era of targeted therapies. Outcomes are favourable when performed laparoscopically and long‐term follow‐up demonstrates sustained haematologic benefit in surviving patients.
Salil Dutt Barrett   +9 more
wiley   +1 more source

A Personalised Vaccination Program Based on Immune Reconstitution in Paediatric Cancer Survivors

open access: yesActa Paediatrica, EarlyView.
ABSTRACT Aims Paediatric cancer survivors often experience treatment‐induced immunosuppression, requiring post‐treatment revaccination. However, immune recovery timelines vary, and current revaccination guidelines, largely based on data of varied quality derived from studies on acute‐lymphoblastic‐leukaemia (ALL), may not be applicable across all ...
Menucha Jurkowicz   +17 more
wiley   +1 more source

Integrating novel therapeutic strategies in myeloproliferative neoplasms: Driving disease‐directed progress

open access: yesBritish Journal of Haematology, EarlyView.
Summary Over the past decade, there has been a substantial increase in the diversity and number of therapeutic options for myeloproliferative neoplasms (MPNs). While many remain within the clinical trial arena, the clinician and patient community have seen more approvals reaching the clinic and a rethink on how best we should be approaching these ...
Trung Q. Ngo   +3 more
wiley   +1 more source

Home - About - Disclaimer - Privacy